Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Pfizer Inc.

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer’s IBRANCE® in Combination with Standard-of-Care Therapies Extends Median Progression-Free Survival by Over 15 Months in Phase 3 PATINA Study in Patients with HR+, HER2+ Metastatic Breast Cancer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces New Chief Scientific Officer and President, Research & Development
From Pfizer Inc.
Via Business Wire
Tickers PFE
European Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance
From Pfizer Inc.
Via Business Wire
Tickers PFE
Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older
From Pfizer Inc.
Via Business Wire
Tickers PFE
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
From Pfizer Inc.
Via Business Wire
Tickers PFE
Tim Buckley Elected to Pfizer’s Board of Directors
From Pfizer Inc.
Via Business Wire
Tickers PFE
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Declares Fourth-Quarter 2024 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
From Pfizer Inc.
Via Business Wire
Tickers BNTX PFE
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
From Pfizer Inc.
Via Business Wire
Tickers PFE
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.